Ryvu Therapeutics receives approval to conduct Phase I/II study of RVU120 (SEL120) in patients with relapsed/refractory metastatic or advanced solid tumors in Spain
Ryvu Therapeutics Presents Clinical and Translational Data Updates at the 63rd American Society of Hematology (ASH) Annual Meeting and the 44th San Antonio Breast Cancer Symposium
We use cookies to ensure that we give you the best experience on our website. If you continue to use this site we will assume that you are happy with it.OkPrivacy policy